Research and Clinical Trials

Title  

ARTESIA

Brief Description  

This study aims to determine if treatment with apixaban, compared with aspirin, will reduce the risk of schemic stroke and systemic embolism in patients with device-detected sub-clinical atrial fibrillation (SCAF) and additional risk factors for stroke.

Who may be Eligible  

Patients with a permanent pacemaker or defibrillator or insertable cardiac monitor capable of detecting SCAF, with at least one episode of SCAF lasting at least 6 minutes but not more than 24 hours.

Start Date  

05/04/2016

IRB Number  

12-15-02A

Principal Investigator  

Saxonhouse, Sherry

Contact Name  

Connie

For More Information, Contact  Connie  , Dellinger
Phone:  (704) 355-4797  Fax:  (704) 355-7264  
Email:  SHVIClinicalResearch@atriumhealth.org
Address:1001 Blythe Blvd, MCP-M-201 Charlotte, NC 28203